Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05741242 Enrolling by invitation - Cancer Clinical Trials

Basket Trial of Neoantigen Synthetic Long Peptide Vaccines in Patients With Advanced Malignancy

Start date: November 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a basket trial of neoantigen synthetic long peptide vaccines in patients with advanced malignancy. Up to 20 subjects will be treated with the neoantigen synthetic long peptide vaccines.

NCT ID: NCT04762862 Enrolling by invitation - Solid Tumor Clinical Trials

QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy

QUANTACT
Start date: February 1, 2021
Phase:
Study type: Observational

"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB). The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets. Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations. "

NCT ID: NCT04260269 Enrolling by invitation - Solid Tumor Clinical Trials

Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study

CardioSwitch
Start date: June 1, 2018
Phase:
Study type: Observational

The purpose of the present study is to evaluate cardiotoxicity during re-challenge of a different modality of fluoropyrimidine (primary end-point S-1 and secondary any other fluoropyrimidine) after having perceived cardiotoxicity with a fluoropyrimidine based regimen previously. The patient population is being treated for solid tumors.

NCT ID: NCT04151329 Enrolling by invitation - Solid Tumor Clinical Trials

A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor

Start date: June 21, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With HER2-positive Advanced Solid Tumor

NCT ID: NCT03229200 Enrolling by invitation - Solid Tumor Clinical Trials

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Start date: May 22, 2017
Phase: Phase 4
Study type: Interventional

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

NCT ID: NCT02093325 Enrolling by invitation - Solid Tumor Clinical Trials

A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia

Start date: March 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is evaluate the efficacy and safety of eltrombopag as a rescue of isolated chemotherapy-induced thrombocytopenia in patients with solid tumor .